Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.11-05

Editas Medicine (NASDAQ:EDIT) Third Quarter 2024 Results Key Financial Results Revenue: US$61.0k (down 99% from 3Q 2023). Net loss: US$62.1m (loss widened by 38% from 3Q 2023). US$0.75 loss per share...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481760345?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-05 18:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481760345","market":"us","top_or_hot":-1,"title":"Editas Medicine Third Quarter 2024 Earnings: Misses Expectations","media":"Simply Wall St.","content":"<div>\n<p>Editas Medicine (NASDAQ:EDIT) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$61.0k (down 99% from 3Q 2023).\nNet loss: US$62.1m (loss widened by 38% from 3Q 2023).\nUS$0.75 loss per share...</p>\n\n<a href=\"https://finance.yahoo.com/news/editas-medicine-third-quarter-2024-104333575.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Third Quarter 2024 Earnings: Misses Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Third Quarter 2024 Earnings: Misses Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 18:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/editas-medicine-third-quarter-2024-104333575.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Editas Medicine (NASDAQ:EDIT) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$61.0k (down 99% from 3Q 2023).\nNet loss: US$62.1m (loss widened by 38% from 3Q 2023).\nUS$0.75 loss per share...</p>\n\n<a href=\"https://finance.yahoo.com/news/editas-medicine-third-quarter-2024-104333575.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EDIT","symbol_name":"Editas Medicine, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/editas-medicine-third-quarter-2024-104333575.html","article_id":"2481760345","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481760345","pubTimestamp":1730803413,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqGS:EDIT Earnings and Revenue Growth November 5th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 98%. Earnings per share  also missed analyst estimates by 3.4%.Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 12% from a week ago.Before you take the next step you should know about the 1 warning sign for Editas Medicine that we have uncovered.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EDIT":"Editas Medicine, Inc."},"translate_title":"Editas Medicine 2024年第三季度收益：未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":1},"content_text":"Editas Medicine (NASDAQ:EDIT) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$61.0k (down 99% from 3Q 2023).\nNet loss: US$62.1m (loss widened by 38% from 3Q 2023).\nUS$0.75 loss per share (further deteriorated from US$0.55 loss in 3Q 2023).\n\n\n\n\n  NasdaqGS:EDIT Earnings and Revenue Growth November 5th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nEditas Medicine Revenues and Earnings Miss Expectations\n Revenue missed analyst estimates by 98%. Earnings per share (EPS) also missed analyst estimates by 3.4%. \n Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are down 12% from a week ago. \nRisk Analysis\n Before you take the next step you should know about the 1 warning sign for Editas Medicine that we have uncovered. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481760345"}